pentobarbital will decrease the extent or result of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unfamiliar.
pentobarbital decreases amounts of elvitegravir/cobicistat/emtricitabine/tenofovir DF by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May produce lack of virologic response and achievable resistance.
pentobarbital increases outcomes of ifosfamide by impacting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Coadministration of ifosfamide with CYP2B6 inducers may possibly improve metabolism of ifosfamide to its metabolite. Watch for enhanced effects/toxicities if combined with CYP2B6 inducers.
pentobarbital will lower the level or effect of fosamprenavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital raises toxicity of buprenorphine, long-performing injection by pharmacodynamic synergism. Modify Therapy/Keep track of Carefully. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases possibility of adverse reactions like overdose, respiratory depression, and Demise. Cessation of benzodiazepines or other CNS depressants is most popular typically.
pentobarbital will reduce the extent or outcome of elagolix by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
With therapeutic doses of TCAs, barbiturates enhance metabolism and decrease blood concentrations of TCAs.
pentobarbital decreases outcomes of hemin by pharmacodynamic antagonism. Use Warning/Check. Prescription drugs that boost delta-aminolevulinic acid synthetase may possibly lessen hemin impact.
pentobarbital will decrease the level or result of etravirine by influencing hepatic enzyme CYP2C9/ten metabolism. Use Caution/Monitor.
pentobarbital will minimize the level or outcome of siponimod by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Coadministration website of siponimod which has a drug that causes average CYP2C9 additionally a moderate or potent CYP3A4 inducer is not really suggested.
pentobarbital will decrease the extent or impact of oliceridine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. If coadministration using a CYP3A4 inducer is important, look at growing oliceridine dose right until secure drug outcomes are attained; observe for indications of opioid withdrawal.
pentobarbital will lessen the level or impact of rabeprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.
Phenytoin and barbiturate blood degrees must be monitored extra regularly if supplied concurrently; outcome of barbiturates on phenytoin metabolism noted being variable; sodium valproate and valproic acid seem to minimize barbiturate metabolism; keep track of barbiturate blood stages and make appropriate dosage changes as important
pentobarbital raises toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. CYP3A4 inducers may possibly enhance the metabolism of ifosfamide to its Energetic alkylating metabolites.